i¦É¨¢ÄàCjqÅÍw 3 NÅ 8`12CnWjZ 3 N¶ÅÍ26`40ÉBµCqÅÍZ 1Peto Æ Lopez çÌ WHO ZÉæéÆ1995N

NÈ~ÁµCZ 1 NÅ 3`8ÅéªCÉÍiÉæé´ßSªS¢EÅ3125000

Z 3 NÅÍ 5`15ÉB·é4)DiKµÌ{¿

lCú{ÅÍ 9 5000lÆv³êCÅß20NÔÍjR`Ë¶ÇÅèCêxiðÍ¶ßéÆ

Åñ 2 {ÉÁµÄ¨èC±ÌXüÍ³çÉ±Ö·é±ÆÍ¢ïÅé±Æðl¦éÆC«­±Æª\ª³êÄ¢é1)DiÉæÁÄ¥®¬ÌzÂí¾³ÌXNt@N^[ÆµÄÌiª¾³â]²ÈÇÌzÂí¾³Ì­ÇXNª¶Ìú©ç`¬³êÄ¢é±ÆÉÈèCJÜé±ÆÍC¢ÄÌuwI¤É¨¢Äm§³ê¶·×«»óÅÄ¢éDú{Åà 6 {§Rz[g¤2)CåãsC

êÊ¯Éæì¯Äáº·é±ÆªÏ@³êÄ¢V§ÌV­csÌ¤âCNIPPON DATA803)

é±Æ©ç·éÆCãÃ]ÒÌÖyÉÊ½ÈÇÌ¤É¨¢ÄCiÆ¥®¬¾³ë³E·×«ðÍå«¢Æl¦çêéDSC]²Ìë³ESÖÌe¿ª¾ç©É³êÄ¢éDéDæiÅÍãtÌi¦ª{eÅÍCzÂí¾³XNt@N^[ÆµÄÌiÉÂ¢ÄÌÅßÌm©ðÐîµ½¢D

Æ±ëªC½¬10Nxi1998NxjiÆNâèÉÖ·éÀÔ²¸ÅÍCzÂí¾³ªiÉæÁÄ©©èâ·­Èé±ÆðmÁÄ¢élÌÍCxªñ84.5âDPÖÌe¿79.6ÆäigzÂí¾³
A.

SÇ¾³æµªÑª»ôgVemirµÄá­CSa40.5C]²35.1Å½ Î ±  É Ü Ü ê é ñ 4000 í Þ Ì ¨ ¿ Ì ¤éDÜ½CíªÌ¬li¦Í½¬12NxÅ¿CLQ¨¿ÆµÄFè³êÄ¢éàÌÍñ200j«47.4C«11.5ÅíÞÉÌÚéD»Ì¤¿Ì 1 ¬ªÅèCæiÌ¤¿éjR`ÅÍj«i¦Í¾É­C20`30ÎãÌÍtç¿ðhµÄJeR~ðV£µC«i¦ÍÁXüÉÇûkÆ³ã¸CSÁð«½·DjR`

mKey words néD³çÉC¢¬NÒÌi#SÇ¾³#]²#æµªÑª»ô#Ö
ú{zÂíwïêåãzÂíêåãæA@ªæQ B@@BNA@

CEIÈOÉà­ÍÈÇûk¨æÑCÇxûkìp

³ ê ½ D NIPPON DATA803) Å Í i  Ì S ¾

ég{LT A2 ªV£·éDÜ½å¬³CSzÂí¾³ÖÌe¿à¢³êÄ¨èCj  É Í ê _ » Y f ª ñ 90  ö x Ü Ü ê Ä ¨«É¨¢ÄÍi 1 ú20{ÈàÅÌS¾³SÌèCÌwOrÆ­ÍÉ·é½ßÉ¦ÌÎë¯xÍ4.2{Å«Ì_fRóÔÆÈèC^®ÏeÊÌáºðê7.4{ÆS¾³S¦Éiª½åÈe¿ð«½·Ù©C½ÇÆÈéDÇàçªáQ³^¦Ä¢é±Æª¦³ê½D

êCHDL RXe[àáºµC®¬d»ð
£i·éD

èC1 ú21{ÈãÌó®iàSÇ¾³ÌdvÈë¯öqÅéÆ½ñ³êÄ¨èCAHA Í1992NÉSiÆ«S¾³ÉÖ·éuw²¸Ì¤¿CÌXNÍÆëÉ¨¯éó®iÅÍñ30ãÄÌ Framingham Study, Albany Study ÈÇÌ¸µCó®iÌöxª³çÉ¢EêÅÍCæ5 ÂÌåvuw¤ðµ½ Pooling Project5)è¢XNªÅÍC1 ú 1ÌiÉæé«S¾³ë³ÌÎë¯xÍ2.5{ÅÁ½Dú{É¨¯éåKéÆµÄ¢é6)DÜ½ó®iÍ\hÂ\ÈzÂí¾³ÌÅåÌ´öÌêÂÅèCñiÒªó®iÉ³ç³êé±Æðh®

ÍÈuw²¸É¨¢Äà\PÉ¦·Æ¨èC¯l½ßÉÌiÌ«S¾³ë³ESÉÎ·éÎëéDOtsuka ç7) ÍCíñiáN{eB¯xÍ1.7`2.4{ÅéÆñ³êÄ¢éDÅßAÉ¨¢Äí¸©30ªÌó®iªÇàç@Ì¢E50ÈãÌªQÁµÄsíê½20000\É«e¿ðyÚµ¥¬\õ\ðáº³¹é±¼ÈãÌSØ[Ç³ÒðÜÞåKÍ± INTER_

ÆðCo¹Çhv[SGR[@ðp¢Ä¦µçäéwÍð·éKvªéÆµÄ¢HEART ±ÅÍCiÉæéSØ[ÇÌX½Dí¸©Èó®iÅàë¯Å

NÍ3.02{i1 ú1`9{Å1.49{C10`19{Ålª½Î±\I©çÛì³êÈ¯êÎÈçÈ¢2.68{C20{ÈãÅ4.71{jÅ±Æª¦³ê½f[^ÅèC³2.68{CAa3.02{CìiBMI30j1.23{C^èC·×ÄÌéDÅßÌXüÆµÄgy¢½Î±hC·Èí¿á

®0.72{CAR[ÛæÅ0.78{C¤Âa1.56jR`Cá^[ÌàÌªå¬ÆÈèC{Ì¼ÌöqÆärµÄàCÖÌdv«ª¦ày¢½Î±Å\P½©

êÎNíQª­È¢æ¤Év

iKµg«S¾³Îë¯xij«jðÍNîw

¯×ôÄ
¢EG äoteborg Prevention studyÄ Illinoi
Pooling Project5)
ú{vR¬

endpoint

AA^

MæÔ

DG`EE

ë³FE`GD

S

C.@
@
A.ID

D@`EI

ë³

B.E
@

B.A@`C.A@

A.I@`E.BB
p@.A

D@`

ë³B.C
H

LsE·èsSNî

ë³B.@
@

U{§Rz[gi½RRz[gj2)åãsD@`

SA.GAõ

D@`EI

ë³A.GAp@.@EV­cs
NIPPON DATA 803)

D@`C@`FIiJnjë³
S

A.H
I
A.HG

A.@C`C.DF
A.B
A`B.IAdñAªÍi¼Ìë¯öql¶·ÝjCõ SiÒiuiÆN\iÆNâèÉÖ·é¢ïñvC2002N 6 æèøpêüÏjCF@ú{zÂíwïêåãzÂíêåãæA@ªæQ B@@BNA@í¹éXüªéªCjR`ûÊiêèðÅÄà©ß²¹È¢DêèÊÌå¬ÌjR`ÊðªèD½Î±pbP[WÉLÚ³ê½jR`ÊjÊÉSØ[Ç­ÇÉ^¦ée¿ðÝ½ Palmer çÌñ8) i\B.

]²æµªÑª»ôgVemiiÉæè]²­ÇÌXNª­Èé±ÆQjÅÍCájR`Eá^[½Î±ªSØ[ÍC¢ÄÅÍm§³ê½uwIÀÅÇ­ÇÌÎë¯xð¸ç·±ÆÍÈ¢Æ³êÄÉÍ¦³êÈ©Á½«Ì]²­ÇXNà¢éDÜ½C{ð¸ç·¸ÌøÊÉÂ¢Äj«ÆÏíçÈ¢±ÆªCÄÌ«ÅìtñéªCßàCiÒªÊíÌ{Ì¼ªÌið·éÆC12lð12NÔÇÕ²¸µ½f[^Å¾ç©É[­pñÉz¤C1 {ð½­³ñz¤ÈÇÌã³ê½11) Dú{É¨¢ÄÍCiª]²­Ç

s×ªN±èC©¦ÁÄjR`Zxâë¯öqÅHbCO ÈÇÍã¸µ9) i\RjC¸ÌøÊÉÂ¨¢ÄÍ¾ÄÅÍÈ©Á½ªCNIPPON DATA¢ÄÍ^â³êÄ¢éD803)ðÍ¶ßÆ·éÅßÌ¤ÅÍCú 1

ú{lÉ½¢¥¹k«·SÇÉ¨¢ÄàCié10) D»Ì¼Cª¥¹kÌdvÈë¯öqÅÂÇ«®¬d»Çâ Buerger aÌë¯öqÆµé±ÆÍCú{ÌßÌuw¤Éðz¤iÒÍñiÒÆä×Ä 2`3 {ÌÎë¯xÅé±Æª¦³ê½D±Ìæ¤ÈÏ»ÍCßÌ]²Í³Ìe¿ª­­C¯Ì³ªÅå³Å1965N©ç1990NÌÔÉñ15\QlHiuj³§è¿ÄmÇ¯½ïûÊJ~^iÒmñvISØ[ÇÎë¯xÇ¯½ïûÊ
img/{j³ÒlÎÆ Îë¯xñiÒ»iÒ

AIA

ID
@ACD
F
H

D
E
AC
C

D.G
C.C

B.H`H.@
B.C`D.H@.FD`@.G
E

GE

AE@

C.B

B.B`D.E@.GF`A.@@
A.@
A`A.@F

ABF
A
AB

AFC
AGB

D.G
C.F

C.D`F.E
B.F`E.@

A.@
G`A.B
I
A.C@

GB
CF

IHDAE.A
D.B

C.D`G.E
B.D`G.B

@.D@@.D@`@.FCIE÷MÀEmmHg àáºµC]²a^à]àoª¸­µ][Çª¦C´RXe[lªã¸·éÆÆàÉ]²Ìa^ª¢ÄÉßÃ¢Ä«Ä¢
é±ÆÉæéàÌÆl¦çêÄ¢éDC.

ñiÒð1.0Æ·é
iPalmer JR et al: N Engl J Med 1989; 320: 1569_1573
æèøpjig\m¼mzÂí¾³æµªÑª
»ômÖA

a.

iÒÅÍCñiÒæèà³lª«úÅá¢XüÉ

i{¼¸V^êmiÒmÇ¯½ïZxgê_»YfÔÞ«éÏïZxiCOHbjmÖWinAFj
COHb Ç¯½ïZxAúmi{ i÷jing/ml jÊíÌi
E@÷¸

C@AE

G.G
G.IAGB
D.H

iHo_yen Do et al: Br Med J, 1982; 284: 1905_1907æèøpj
ú{zÂíwïêåãé±ÆÍL­FßçêÄ¢éªCÖÉæÁÄ³Íã¸¹¸C³Íáº·é12).
b.

AaiÍCX´ó«ðáº³¹é½ßCAaÌ­ÇXNàßé±ÆªCÅßÌRz[g¤ÉæÁÄñ³êÄ¢é13)Dc.

\R³¿ãÓiKµÆ´¿ÌÖAðùðCìxCN
îðl¶µÄ¢µ½¤É¨¢ÄC1ÌiÉæÁÄCHDL RXe[Í3.3 mg/dlá­ÈèCÖÉº¢ HDL RXe[ªã¸·é±Æªñ³êÄ¢é14)DD.

ÖgzÂí¾³ÖÉæé¥®¬¾³ÌXN¸­øÊÉÂ¢zÂíêåãæA@ªæQ B@@BNA@CFAÄÍCFramingham StudyCvR¬¤ðÍ¶ßàOÌ¤Å¾ç©ÅE.

éD}«SØ[ÇðN±µ½ãÌÄ­ÌXNðÝ½ Sato çÌñÅzÂí¾³§ÅåïjIPÖimÊutP½¬13Ni2001NjÉo³ê½zÂíaÌfÍC±µÄiµ½àÌÍ30ß­Ä­µ½fÆ¡ÃÉÖ·éKChCi1999_2000NxªCÖ·éÆñ 3 ªÌ 1 É¸­µCSa¯¤ÇñjÉ¨¯é«S¾³Ìê\Sà 2 ªÌ 1 ÈºÉ¸­µ½D¥®¬oCpX

hKChC16) Åàg®SÖhªñ¥³êpðó¯½ 415 lÌ³ÒÌCèpãÌióµ½D»Ì¼CSØ[Çñ\hÉÖ·éKChª\ãÉÇÌæ¤ÉÖW·é©ÉÂ¢Ä¢µ½

CC¥®¬¾³É¨¯éC^[xV¡Voors ç15) ÉæéÆC15NÜÅÌ follow up úÔÃÌKKChCC«SsS¡ÃKChÉiÒÍÖÒÌ2.5{ÌSØ[ÇÌXNªCÉ¨¢ÄàÖÌiªñ¥³êÄ¢éD

é±Æª¦³êÄ¢éD³çÉÄ¥®¬oCp

AHA ªÅßüèµ½KChC17)ÆÌärð

Xpâpã·SÇXNàèpãÖ·éÆLÓ\SÉ¦·DÄÉ¨¢ÄÍC1992NÉ JCAHOÉ¸­·é±Æª¦³êÄ¢éªCÄi·éÆ(Joint Commission on Accreditation of Health­»ÌXNÍÜ½ã¸·éDÁ¦ÄSØ[ÇCÄcare Organizationsjª½Î±ÎôÌîðüè¥®¬oCpXpC·SÇÌXN·×ÄÉ¨¢µCãwIRÉîÃ«ãtÌw¦ÅiªÂÄCÖÒÍñiÒÆ·ÍÈ¢Æ³êÄ¢éD³ê½àÌÈOÍa@¨à®SÖÆµ½19)D
1994NC1998NÉ²¸ªsíêÄ¢éªC1998
NÌ²¸ÉæéÆC96Ìa@ª±ÌîðNAµÄ¢½Æñ³êÄ¢é20) DíªÉ¨\S

ú{g AHA mijÖX§Ååïmärú{jIPzÂíamffg¡ÃjÖX§Ååï««S¾³Ìê\hKChC16)¶KµiijF®SÈÖðÀ{Có®iàñð·×«Å«SØ[Çñ\hÉÖ·éKChCñò¨Ã@ÖéNXÛFSØ[ÇãÌÖNXÜaFAj ó®Öðð¯é
Bj jR`KÜ½ÍjR`pb`ÉæéjR`ÖfÇóÌÉa

«¥®¬¾³É¨¯éC^[xV¡ÃÌKKChC
PTCA ãÌÇF¥®¬ë¯öqÉÎ·é¡ÃiÖCjR`KCjR`pb`ÈÇÌgpj
««SsS¡ÃKChCêÊÇ iFiÍ·×ÄÌ³ÒÅÖ~·×«Åé

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update17)
Guide to Primary Prevention of Cardiovascular Disease and Stroke: Risk InterventionXNîüÆÚWiÚWF®SÈÖÆÂ«^oRÌ®Sñð©

óf·é½ÑÉióµÉÂ¢ÄqËé×«ÅéD·×ÄÌÖÒÉÖ·éæ¤C¾mÉCfÅÆµÄCÂXlÉí¹½û@ÅAhoCX·éDiÒÌÖµæ¤Æ·éÓuð]¿µÄCJEZOâÖÌvæð½Ä
é±ÆÉæÁÄ·éDÖÁÊvOâò¨Ã@ðQÆµÄCÖÌoßðÝéD
EêâÆëÅÌó®iðð¯éæ¤É·éDCFB

ú{zÂíwïêåãzÂíêåãæA@ªæQ B@@BNA@¢ÄàC±ÌÉ­B·é±ÆªØ]³ê

care, American Heart Association. Circulation 1992;
86: 699_702

éD7) Otsuka R, Watanabe H, Hirata K et al: Acute eects ofpassive smoking on coronary circulation in healthy
young adults. JAMA 2001; 286: 436_441

Ij8) Palmer JR, Rosenberg L, Shapiro S: ``Low yield''

Ji_ÅÍ2001N 1 ©ç½Î±pbP[WÌå«È 2 ÊÌ­È­Æà50ÉÊ^\¦Åx\¦ª³êCgiÍSaÌ´öhgiÅ]²ÉÈéhÈÇÆ©êÄ¢éD»êÉä×éÆíªÌ½Î±pbP[WÌx¶ÍñíÉBÈ\»µ©³êÄ¨ç¸CiÎôàxêðÆÁÄ¢éÆ¢¦éDzÂí¾³Ì\h¨æÑ¡ÃÌ½ßÉÍC·×ÄÌiÒÉÏÉIÈÖð¤
Èª·w±ðs¤KvªéÆÆàÉCó®ià\®iÆ¯¶­zÂí¾³­ÇÉñ^·é½ßCó®iðàOêIÉð¯éæ¤©·×«ÅéDµ½ªÁÄC¡ãzÂíãÃÉgíéÒÆµÄÍ©çªiµÈ¢ÌÍRÅéªCÏ

ÉIÉa@{ÝÌ®SÖâÖxCih~³çÉæègñÅ¢­Kvª

éÅë¤D

cigarettes and the risk of nonfatal myocardial infarction
in women. N Engl J Med 1989; 320: 1569_15739) Ho­yen DO, Spence VA, Moody JP et al: Why smoke
fewer cigarettes? Br Med J 1982; 284: 1905_1907
10) Yasue H, Kugiyama K : Coronary spasm: clinical fea­tures and pathogenesis. Int Med. 1997; 36: 760_76511) Golditz GA, Bonita R, Stampfer MJ et al. Cigarettesmoking and risk of stroke in middle­aged women. NEngl J Med 1988; 318 937_94112) Minami J, Ishimitsu T, Mtsuoka H: Eects of smoking
cessation on blood pressure and heart rate variability inhabitual smokers. Hypertension 1999; 33: 586_59013) Rimm EB, Chen J, Stampfer MJ, et al: Cigarette smok­
ing and the risk of diabetes in women. Am J PublicHealth 1993; 83: 211_21414) Gerace TA, Hollis J, Ockene JK et al: Smoking cessa­tion and changes in diastolic blood pressure, bodyweight, and plasma lipids. Prev Med 1991; 20: 602_620
15) Voors AA, van Brussel BL, Plokker HW et al: Smokingand cardiac events after venous coronary bypass sur­q¶£q1) Peto R, Lopez AD, Boreham J et al: Mortality fromtobacco in developed countries 1950_2000. Oxford
Univ Press, Oxford, 19942) ½RYFiÆ®¬d»ÆÌÖWÉÖ·éuwI¤F
ñ27lÌ40ÎÈãÌ¬l13NÔp±Ï@¬ÑðSÉDÅVãw 1981; 36: 798_8093) ]²ÈÇÉæéQ½«èESÌNë¯x]¿VXeJ­ÆÇF1980NzÂí¾³îb²¸ÇÕ²¸ñCú{zÂíÇ¤¦cïCC19954) ì¨ONCº³aCå¾Ù©FÂ­NÌiEùðs®\Japan Know Your Body Study ÌÊæè\Dúöq 1991; 38: 885_899
5) The Pooling Project Research Group: Relationship ofblood pressure, serum cholesterol,smoking habbit,

relative weight, and ECG abnormalities to incidence ofmajor coronary events : Final report of the Pooling
Project. J Chron Dis 1978; 31: 201_306
6) Taylor AE, Johnson DC, Kazemi H: Environmental
tobacco smoke and cardiovascular disease. A position
paper from the council on cardiopulmonary and critical

ú{zÂíwïêåãgery: A15_year follow­up study. Circulation 1996; 93:42_4716) k©°CÂqOdCåàÑ`Ù©F«S¾³Ìê
\hKChCDJpn Circ J 2001; 65 SupplX:999_106517) Pearson TA, Blair SN, Daniels SR et al: AHA Guide­lines for primary prevention of cardiovascular disease
and stroke: 2002 update. Consensus panel guide tocomprehensive risk reduction for adult patients
without coronary or other atherosclerotic vascular dis­eases. Circulation 2002; 106: 388_39118) Nelson DE, Giovino GA, Emont SL et al: Trends incigarette smoking among US physicians and nurses.
JAMA 1994; 271: 1273_127519) Scoring guidelines addressing smoking policy for theAMH, (Accreditation Manual for Hospitals). VolumeII. Joint Commission on Accreditation of Healthcare
Organizations. Jt Comm Perspect 1993; 13: A1_320) Longo DR, Feldman MM, Kruse RL et al: Implement­
ing smoking bans in American hospitals: results of anational survey. Tob Control 1998; 7: 47_55

zÂíêåãæA@ªæQ B@@BNA@CFC